ERGOOTCinactive

ENTIA BIOSCIENCES, INC.

Healthcare·Oncology·Pre-clinical·Sherwood, OR, United States
OncologyNeurologyImmunologyHematologyNephrology

ENTIA BIOSCIENCES, INC. (ERGO): 3 pipeline candidates · 2 clinical trials. Updated within the last hour.

6.0/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.22 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ENTIA BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$20K

Cash

$76K

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (3 candidates)

DrugPhase
ergod2Preclinical
ergod2 hemoPreclinical
ergod2 neuroPreclinical
2 clinical trials·CEO: Mr. Timothy A. Timmins

Frequently asked questions

How many drug candidates are in ENTIA BIOSCIENCES, INC.'s pipeline?

ENTIA BIOSCIENCES, INC. (ERGO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ENTIA BIOSCIENCES, INC.'s lead drug candidate?

ENTIA BIOSCIENCES, INC.'s most advanced tracked candidate is ergod2 (Preclinical) for Chronic kidney disease.

What is ENTIA BIOSCIENCES, INC.'s market capitalization?

ENTIA BIOSCIENCES, INC.'s market capitalization is approximately $20K.

Who is the CEO of ENTIA BIOSCIENCES, INC.?

Mr. Timothy A. Timmins is the chief executive officer of ENTIA BIOSCIENCES, INC. (ERGO).

Get the full picture on ENTIA BIOSCIENCES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar